My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Gilead Sciences (NQ:GILD)

127.18 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9

...

48 49 Next >

Uncover the latest developments among S&P500 stocks in today's session. ↗

November 18, 2025

Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

Via Chartmill

Gilead Sciences's Options: A Look at What the Big Money is Thinking ↗

November 17, 2025

Via Benzinga

Healthcare Sector Navigates Mixed Market Close: A Beacon of Stability Amidst Uncertainty

November 14, 2025

As the broader market concluded with a mixed performance on November 14, 2025, the S&P 500 Healthcare sector once again underscored its often-defensive nature, demonstrating resilience amidst an...

Via MarketMinute

Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown ↗

November 09, 2025

Via Stocktwits

1 Healthcare Stock to Own for Decades and 2 We Avoid

November 13, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,...

Via StockStory

Topics Stocks

Tech Sector Tremors: Is the AI Bubble Deflating, and What's Next for the Market?

November 13, 2025

As of mid-November 2025, a palpable unease has settled over the technology sector, long the darling of investors and the primary engine of market growth. After a period of unprecedented outperformance,...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Gilead’s Experimental One Pill Regimen Proved Non-Inferior To Multi-Pill Regimens In Treating HIV ↗

November 13, 2025

The company now plans to submit the data from the study to regulatory authorities.

Via Stocktwits

Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial ↗

November 13, 2025

Gilead's Phase 3 ARTISTRY-1 trial shows its single-tablet HIV regimen of bictegravir and lenacapavir matches the efficacy and safety of current therapy.

Via Benzinga

Explore the top gainers and losers within the S&P500 index in today's session. ↗

November 13, 2025

Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.

Via Chartmill

2 Supercharged Dividend Stocks to Buy Now ↗

November 13, 2025

Innovative drugmakers often make for solid dividend stocks. These two companies are great examples.

Via The Motley Fool

Topics ETFs Intellectual Property

This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

November 13, 2025

Via Benzinga

Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know

November 11, 2025

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...

Via StockStory

Topics Artificial Intelligence Stocks

Is the AI Rally a Bubble? Impact on Commodity Demand and Defensive Stock Rotation

November 11, 2025

As November 2025 unfolds, a subtle yet significant shift in market sentiment is becoming increasingly palpable among financial analysts and retail investors alike. What was once an almost universally...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds

November 10, 2025

New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers...

Via MarketMinute

Topics Artificial Intelligence Economy Government

What's going on in today's session: S&P500 movers ↗

November 07, 2025

Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Gilead's Trodelvy Misses Main Goal In Breast Cancer Study But Shows Early Survival Trend ↗

November 07, 2025

Gilead's Trodelvy missed a key goal in breast cancer, while Livdelzi showed durable efficacy and safety in long-term liver disease studies.

Via Benzinga

Navigating the Volatility: Q3 2025 Earnings Season Delivers Both Cheers and Concerns

November 06, 2025

The third-quarter 2025 earnings season, largely drawing to a close in early November, has proven to be a dynamic and often surprising period for investors. While a significant majority of S&P 500...

Via MarketMinute

Topics Artificial Intelligence Economy Stocks

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Via MarketMinute

Topics Intellectual Property

Gilead Sciences’s Q3 Earnings Call: Our Top 5 Analyst Questions

November 06, 2025

Gilead Sciences’ third quarter was marked by strong sales growth in its HIV and liver disease portfolios, but the market responded negatively due to ongoing concerns about oncology revenue and broader...

Via StockStory

Topics Earnings

3 Cash-Rich Stocks With High Growth Potential Right Now ↗

November 05, 2025

Via MarketBeat

10 Health Care Stocks Whale Activity In Today's Session ↗

November 05, 2025

Via Benzinga

Gilead Sciences Inc (NASDAQ:GILD) Appears as a Decent Value Stock ↗

November 05, 2025

Gilead Sciences (GILD) appears undervalued with a low P/E ratio, strong profitability, no debt, and a solid dividend, fitting classic value investing principles.

Via Chartmill

Moderna Earnings: What To Look For From MRNA

November 04, 2025

Biotechnology company Moderna (NASDAQ:MRNA) will be reporting results this Thursday before the bell. Here’s what investors should know.

Via StockStory

AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential

November 04, 2025

The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central...

Via TokenRing AI

Topics Artificial Intelligence

Gilead Sciences Inc (NASDAQ:GILD): A Dividend Stock with a Secure Payout and Strong Fundamentals ↗

November 03, 2025

Gilead Sciences (GILD) offers a 2.64% dividend yield with a very low payout ratio, strong profitability, and a debt-free balance sheet, making it a compelling dividend stock.

Via Chartmill

Amgen Earnings: What To Look For From AMGN

November 02, 2025

Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings this Tuesday after market close. Here’s what to look for.

Via StockStory

Topics Artificial Intelligence

What To Expect From Myriad Genetics’s (MYGN) Q3 Earnings

November 01, 2025

Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results this Monday after the bell. Here’s what to expect.

Via StockStory

Vertex Pharmaceuticals (VRTX) Q3 Earnings: What To Expect

November 01, 2025

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results this Monday after market hours. Here’s what you need to know.

Via StockStory

Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout

October 31, 2025

Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant...

Via MarketMinute

Topics Intellectual Property

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026 ↗

October 31, 2025

Gilead beats estimates, raises 2025 guidance, driven by strong HIV and liver drug sales and multiple launches planned for 2026.

Via Benzinga

Topics Earnings

< Previous 1 2 3 4 5 6 7 8 9

...

48 49 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.